All peptides
AntimicrobialFDA Approved

Enfuvirtide (Fuzeon)

Subcutaneous injection (twice daily)
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

A 36-amino acid synthetic peptide that inhibits HIV-1 entry into CD4+ T-cells by blocking the gp41-mediated membrane fusion step. Enfuvirtide binds to the first heptad repeat (HR1) region of gp41, preventing the conformational change required for viral-cell membrane fusion.

Mechanism of Action

It is the first and only FDA-approved fusion inhibitor and is active against HIV-1 strains resistant to other antiretroviral drug classes.

Research Summary & Key Findings

FDA-approved in 2003 for treatment-experienced HIV-1 patients. TORO trials demonstrated approximately 1 log10 greater viral load reduction when added to optimized background regimen vs. background alone. Limited by twice-daily subcutaneous injections and frequent injection site reactions. Reserved for heavily treatment-experienced patients due to convenience limitations.

Clinical Status

FDA Approved

Enfuvirtide (Fuzeon) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection (twice daily)

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Antimicrobial

Start Your Consultation

Get an AI-proposed Enfuvirtide (Fuzeon) protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Enfuvirtide (Fuzeon).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.